Inhibikase Therapeutics (IKT) has released an update to notify the public and investors about an entry into a material definitive agreement.
Inhibikase Therapeutics, Inc. has entered into an agreement with H.C. Wainwright & Co., LLC to potentially issue and sell up to $5,659,255 of its common stock through at-the-market offerings. This will be conducted under an existing shelf registration statement and a prospectus supplement. The Company is not obligated to sell any shares but may direct sales at its discretion and can suspend or terminate the agreement. The sales agent receives a 3% commission and has been granted indemnification rights and reimbursement of legal fees up to specific limits.
For further insights into IKT stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
